本文已被：浏览 32次 下载 14次
Received:March 06, 2024 Published Online:January 20, 2025
Received:March 06, 2024 Published Online:January 20, 2025
中文摘要: 动脉导管未闭是早产儿发生心力衰竭的主要原因之一，可影响早产儿存活及生存质量。目前动脉导管未闭的治疗方式主要包括保守治疗、药物治疗、手术治疗、介入治疗、预防性及靶向治疗，但不同治疗方案的适宜人群尚不清晰，对是否、何时及如何关闭动脉导管仍有争议。低胎龄和低出生体重是发生持续性动脉导管未闭的危险因素，本文对胎龄≤28周的超早产儿及体重＜1 000 g的超低出生体重儿动脉导管未闭的治疗现状及进展进行综述，从各自利弊探讨安全有效的治疗方案。
Abstract:Patent ductus arteriosus (PDA) is one of the main causes of heart failure in premature infants, which can affect the survival and quality of life. At present, the treatment of PDA mainly includes conservative, pharmacological, surgical, interventional, prophylactic and targeted therapies, but the appropriate population of different treatment schemes is not clear, and it is still controversial about whether, when and how to close the ductus arteriosus. Low gestational age and low birth weight are risk factors for persistent PDA. This article reviews the current situation and advancements in the treatment of PDA in infants with gestational age ≤28 weeks and birth weight ＜1 000 g, to explore a safe and effective treatment plan by examining the respective benefits and drawbacks of each approach.
keywords: Extremely low gestational age newborns Extremely low birth weight infants Patent ductus arterious Nonsteroidal anti-inflammatory drugs Targeted therapy Ligation of patent ductus arteriosus Transcatheter interventional closure surgery
文章编号： 中图分类号：R72 文献标志码：A
基金项目:四川省卫生健康委员会医学科技项目（21PJ133）；成都市妇女儿童中心医院专项科研项目（2022-12-29）
引用文本：